Healthcare Industry News: allergic rhinitis
News Release - November 7, 2006
Daniel B. Soland Joins ViroPharma as Vice President and Chief Commercial OfficerEXTON, Pa., Nov. 7 (HSMN NewsFeed) -- ViroPharma Incorporated (Nasdaq: VPHM ) announced today that Daniel B. Soland has joined the company as its vice president and chief commercial officer. Mr. Soland will be responsible for the leadership of the company's commercial infrastructure, including sales and marketing, manufacturing, and commercial and market analysis, along with pre-launch activities for late stage product opportunities. He also will be significantly involved in the company's business development and product evaluation efforts as it seeks to expand its product portfolio through the acquisition of complementary late stage or commercial product opportunities. He joins ViroPharma from his previous post as President of Chiron Vaccines.
"Dan will make an outstanding addition to ViroPharma, and his proven track record speaks of his ability to help lead our organization forward," commented Michel de Rosen, ViroPharma's chief executive officer. "Dan's experiences in development, management, and marketing, along with his tireless work ethic, make for a perfect match with ViroPharma's goals and values. His broad pharmaceutical experience across many fields will also bring additional expertise to our already talented business development organization. This experience not only will lend itself well to broadening and maximizing the potential of Vancocin, as we approach and begin preparations for the potential launches of our current clinical opportunities, his leadership and guidance in developing and enhancing future markets for late stage pipeline opportunities will be essential."
de Rosen added, "Dan brings to ViroPharma over two decades of vital experience in launching and building brands and franchises. I am convinced that his contribution to ViroPharma will be considerable, and through the solid foundations set in place by our previous chief commercial officer, Joshua Tarnoff, we will continue to drive ViroPharma's growth."
At Chiron, Soland was most recently responsible for managing the vaccine division to annual sales of $1 billion. Prior to Chiron, he was the president and chief executive officer of Epigenesis Pharmaceuticals, a privately held biopharmaceutical company engaged in developing drugs for use in asthma, COPD and allergic rhinitis. Prior to that, Mr. Soland spent nine years with GlaxoSmithKline as the vice president and director of worldwide marketing operations, and five years as their vice president and director of the U.S. vaccines business unit. Mr. Soland holds a Bachelor of Science degree in pharmacy from the University of Iowa, in Iowa City, IA.
Commented Mr. Soland, "ViroPharma has the assets, the team, the capabilities and the focus to execute on its strategic plans. With two very promising late stage pipeline products moving forward, opportunity for growth in the Vancocin franchise and the potential for continued growth through business development, ViroPharma is well positioned for continued success. I am extremely eager to hit the ground running at ViroPharma at this very exciting time."
About ViroPharma Incorporated
ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin® approved for oral administration for treatment of antibiotic- associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/pulvules_pi.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the Company's website at http://www.viropharma.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.